Verified against NexLife’s public pricing page on September 4, 2026: Monthly $139, 3-month $132/mo, 6-month $125/mo, 12-month $119/mo; flat pricing at every dose; expedited shipping included. Cancellation and membership-fee terms remain Provider Reported pending review of the governing Terms. Source: nexlife.us/pages/semaglutide-all-plans · ledger NX-SEMA-STD-001–011.
<NexLife Semaglutide — standard injection: pricing, plans and evidence status
NexLife — compounded semaglutide (and tirzepatide)
Provider-reported program features, shown as claims pending independent verification. Nothing here is an endorsement; see limitations and our evidence status below.
- 👨⚕️ MD/DO-supervised care (reported)
- 🏥 503A & 503B pharmacies (reported)
- 🧪 Lab review included (reported)
- 📍 Nationwide, subject to licensure (reported)
- ✓ LegitScript-certified (seal verifiable)
- 💰 Flat-rate, dose-independent (verified September 4, 2026)
- 🔁 Care360 coaching (reported)
- 📱 Apple Health / Google Fit sync (reported)
Reported inclusions: medication, all visits, messaging, lab review, and Care360 coaching. NexLife states it does not manufacture or compound medications; compounded medications are not FDA-approved.
Verified pricing: standard injection program. Full evidence: NexLife review.
What we evaluated: NexLife's published Semaglutide — standard injection program across all four plan lengths
Date verified: September 4, 2026
Direct answer: $119/month on the 12-month plan ($1,428 total); $139/month month-to-month
Necessary qualification: Trial evidence for this molecule comes from the FDA-approved injectable product. A compounded product is not that product, though the route of administration is the same.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Pricing by plan length
Monthly equivalent = plan total ÷ plan months. Longer commitment lowers the monthly figure but raises what you pay up front.
| Plan | Monthly equivalent | Total paid | Saving vs month-to-month |
|---|---|---|---|
| Month-to-month | $139 | $139 | — |
| 3-month | $132 | $396 | $21 |
| 6-month | $125 | $750 | $84 |
| 12-month | $119 | $1,428 | $240 |
Semaglutide ODT, 3-month. The card shows a $597 total, $185/month, and a $42 saving. All three cannot be true. $185 × 3 = $555, and $199 × 3 − $42 = $555. Two of the three figures agree on $555, so the $597 total is the outlier. We publish $555.
Semaglutide microdose, 3-month. The card shows $117/month against a $357 total. $357 ÷ 3 = $119, and the stated $30 saving independently confirms the $357 total. We publish $119.
Both corrections make NexLife look marginally worse than its own marketing claims. We publish them anyway, because a publication that only corrects errors in its own favour is not correcting anything.<
What the program price includes
As stated by NexLife:
- The same published program price at every covered dose
- No separate membership fee
- No hidden program fees
- Free expedited shipping
- Licensed-provider evaluation and ongoing medical oversight
- Coaching and patient community access
Evidence status
So the honest trade is this: tirzepatide loses more weight (SURMOUNT-5: −20.2% vs −13.7%, head to head), but semaglutide has the cardiovascular evidence. If you have established cardiovascular disease, that asymmetry may matter more to you than the weight difference. It is also cheaper here — $119/month against $139 for tirzepatide on the same 12-month plan.<
| Trial | Arm | Result | Duration | Comparator | Source |
|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15 mg | −20.9% | 72 weeks | Placebo −3.1% | NEJM 2022 (Jastreboff et al.) |
| SURMOUNT-1 | Tirzepatide 10 mg | −19.5% | 72 weeks | NEJM 2022 | |
| SURMOUNT-1 | Tirzepatide 5 mg | −15.0% | 72 weeks | NEJM 2022 | |
| SURMOUNT-5 | Tirzepatide (max tolerated) | −20.2% | 72 weeks | vs semaglutide −13.7% | NEJM 2025 (Aronne et al.) |
| STEP 1 | Semaglutide 2.4 mg | −14.9% | 68 weeks | Placebo −2.4% | NEJM 2021 (Wilding et al.) |
| STEP 8 | Semaglutide 2.4 mg | −15.8% | 68 weeks | vs liraglutide 3.0 mg −6.4% | JAMA 2022 (Rubino et al.) |
| SCALE | Liraglutide 3.0 mg | −8.0% | 56 weeks | Placebo −2.6% | NEJM 2015 |
| SELECT | Semaglutide 2.4 mg | 20% MACE reduction | ~40 months | Cardiovascular outcomes | NEJM 2023 |
Who is actually who: the entities in this transaction
| Entity | What it is | Regulated by | What it is NOT |
|---|---|---|---|
| Telehealth company | The website you sign up on. Arranges the consultation, handles billing and logistics. | State corporate practice rules; FTC for advertising | Not a pharmacy. Does not make your medicine. |
| Prescribing clinician | The licensed physician, NP or PA who evaluates you and writes the prescription. | Their state medical or nursing board | Not employed by the pharmacy. Must exercise independent judgement. |
| 503A compounding pharmacy | A state-licensed pharmacy compounding for an individual patient against a specific prescription. | State board of pharmacy; FDA for some provisions | Not FDA-approved. Products are not reviewed before marketing. |
| 503B outsourcing facility | An FDA-registered facility that may compound in bulk without patient-specific prescriptions. | FDA, including cGMP inspection | Still not making FDA-approved products. |
| Manufacturer | Eli Lilly, Novo Nordisk. Makes the FDA-approved branded drug. | FDA — full premarket approval | Not involved in compounded products at all. |
Equally: a provider's statement about which pharmacy it uses is a provider-reported relationship until someone verifies it. We label it that way, and so should you when you read it.<
Eligibility, and who is likely to be declined
A licensed clinician decides whether treatment is appropriate. No website can promise you eligibility, and one that implies it should worry you.
Be honest on the intake form. The temptation to shade an answer to secure a prescription is understandable and it is a bad trade: the questions exist because the contraindications are real.
State availability, and why it varies
Availability is decided by two licences rather than by any single rule. The prescribing clinician must be licensed in the state where the patient is located, and the dispensing pharmacy must hold a non-resident licence permitting shipment into that state.
Because those two requirements are held by different parties, a programme can have clinicians licensed in a state and still be unable to ship there, or can pause enrolments in a state without updating its public map. A map describes corporate footprint; it does not describe your eligibility.
The question that settles it takes one message at signup: which pharmacy will fill this prescription, and is it registered to ship into my state? Programmes that name their pharmacies can answer immediately.
Every fee that can be attached to a GLP-1 programme
| Line item | What to ask | How often it bites |
|---|---|---|
| Advertised starting price | Is this a first-month or introductory rate? | Very often — TrimRx, MEDVi, Noom, Eden all advertise intro rates |
| Ongoing price | What do I pay in month two? | This is the number that matters |
| Membership fee | Is it required, and is it billed separately? | Very often — Eden, Mochi, Hims, Hers, Ro, PlushCare |
| Consultation fee | Is the initial visit billed separately? | Sometimes — PlushCare charges $129 initially |
| Laboratory fee | Are baseline labs included or billed to me? | Varies; often unstated until intake |
| Shipping | Included? Expedited? Cold-chain? | Usually included; confirm it |
| Supplies | Are syringes, needles and sharps disposal included? | Usually included on all-inclusive plans |
| Dose-based increase | What do I pay at the highest dose you cover? | Material — MEDVi goes $399 to $499; Shed and Oak escalate |
| Dose ceiling / cap | Is there a maximum dose on this plan? | Material — Noom's $199 plan caps at 0.6mg |
| Upfront payment | How much do I pay today to get the advertised rate? | Found's $169 requires roughly $2,028 up front |
| Renewal price | Does the price change when the plan renews? | Frequently unstated — get it in writing |
| Cancellation terms | If I stop in month three of twelve, what happens to my money? | The most-forgotten question in the category |
A worked example
Two programmes. One advertises $179. The other advertises $186. Which is cheaper?
| Programme A (advertised $179) | Programme B (advertised $186) | |
|---|---|---|
| Month 1 | $179 (intro rate) | $186 |
| Months 2-12 (ongoing rate) | $299 × 11 = $3,289 | $186 × 11 = $2,046 |
| Membership (if any) | $0 | $0 |
| Dose-based increase | None stated | None — flat at every dose |
| Twelve-month total | $3,468 | $2,232 |
| Effective monthly | $289 | $186 |
How it compares
| Program | Month-to-month | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Tirzepatide — standard injection | $169 | $159 | $149 | $139 | $1,668 |
| Tirzepatide — microdose | $159 | $149 | $139 | $129 | $1,548 |
| Tirzepatide — ODT (oral) | $229 | $219 | $205 | $199 | $2,388 |
| Semaglutide — standard injection | $139 | $132 | $125 | $119 | $1,428 |
| Semaglutide — microdose | $129 | $119 | $114 | $110 | $1,320 |
| Semaglutide — ODT (oral) | $199 | $185 | $177 | $165 | $1,980 |
Total paid over twelve months on the 12-month plan. The ODT (oral) forms are the most expensive of both molecules — and the least evidenced.
Frequently asked questions
What does NexLife Semaglutide — standard injection cost?
$119/month on the 12-month plan ($1,428 total), $125 on the 6-month, $132 on the 3-month, and $139 month-to-month. Verified September 4, 2026.
Is there a membership fee?
NexLife states there is no separate membership fee and no dose-based price increase — the published program price covers every dose the program covers. We report that as the company states it.
Is this FDA-approved?
No. Compounded medications are not FDA-approved as finished products and the FDA does not review them for safety, effectiveness or quality before marketing.
Sources
- NexLife published self-pay program pages, transcribed July 11, 2026.
- U.S. Food and Drug Administration — compounding status.
- Our pricing-verification methodology and disclosure policy.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.<
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.<
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.<
Safety, contraindications and monitoring
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
These words are used interchangeably in marketing and they are not interchangeable at all. The distinction decides what evidence applies to what you are actually buying.
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded Semaglutide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.<
The numbers behind this page
Checking the figures in Semaglutide Standard
Every price quoted in Semaglutide Standard comes from the programme's own pricing page and carries the date it was captured. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Where this sits in the market
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Questions this page answers
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.
What is the cheapest verified GLP-1 programme?
NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.